For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the arrival of Vyndamax and Tafamidis meglumine represents a true breakthrough . These novel therapies protect the transthyretin protein, slowing its destructive build-up and alleviating the severity